Loading...
XIST
DEVA
Market cap255mUSD
Nov 12, Last price  
62.90TRY
Name

Deva Holding AS

Chart & performance

D1W1MN
XIST:DEVA chart
P/E
—
P/S
0.65
EPS
—
Div yield, %
0.40%
Shrs. gr., 5y
—
Rev. gr., 5y
59.52%
Revenues
19.25b
+24.50%
181,921,280267,264,880216,985,507332,640,465385,659,898404,973,563419,510,418418,391,085467,940,004576,380,100688,456,364800,295,1121,040,677,0481,373,983,5411,863,328,5012,330,367,7914,477,917,31311,330,314,02115,458,482,05019,245,645,072
Net income
-807m
L
-48,872,14090,605,540-91,433,418-8,185,395-1,600,891-15,633,95534,240,84324,603,6708,722,94247,659,66860,331,10192,542,675136,361,117286,015,741651,448,6841,170,087,4761,360,224,2213,385,418,49169,419,646-806,988,481
CFO
2.75b
-45.79%
-28,468,790-60,216,170-73,313,673-18,698,883480,740-4,592,2616,537,89350,037,22351,491,51288,579,902187,441,072110,844,831130,983,784441,236,234637,391,8701,247,774,934815,910,9802,310,120,8995,067,374,2392,747,007,150
Dividend
Jun 25, 20240.25 TRY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Deva Holding A.S. is a Turkish pharmaceutical firm specializing in the development and distribution of a wide array of medicinal goods. Its extensive portfolio encompasses treatments for various conditions, including cancer (antineoplastic agents), immune system disorders (immunomodulating agents), skin ailments (dermatological products), hormonal imbalances (systemic hormonal preparations), and infectious or parasitic diseases (anti-infective and antiparasitic products for systemic use). Additionally, the company offers dietary supplements and electrolyte solutions. Deva Holding also supplies pharmaceuticals targeting major bodily systems such as the urogenital and reproductive systems, blood and hematopoietic organs, the cardiovascular system, musculoskeletal system, nervous system, digestive tract and metabolism, respiratory system, and sensory organs. Furthermore, its offerings include specific drug classes like cephalosporins and penicillin, inhalation therapies, both solid and liquid oncological preparations, and veterinary pharmaceuticals. It also produces active pharmaceutical ingredients (APIs), various sterile dosage forms such as ampoules, liquid and lyophilized vials, and ophthalmic drops, alongside medical ampoules for sterile injectables; cologne is also part of its product line. Beyond its domestic operations, Deva Holding exports its products to approximately 60 nations globally. Established in 1958, the company maintains its headquarters in Istanbul, Turkey, and operates as a subsidiary of Eastpharma S.à R.L.

Key people

Chairman of the Board, Chairman of the Management Board, Chief Executive Officer · since 2009
Vice Chairman of the Board - Representing Vetas Veteriner ve Tarim Ilaclari AS, Vice General Manager - Finance · since 2009
Riza Yildiz
Financial Reporting and Accounting Director
Dogan Varinlioglu
Marketing and Sales Director
Aysecik Haas
Member of the Board
Tuncay Cem Akkus
Independent Member of the Board
Cuneyt Demirgures
Independent Member of the Board · since 2012
IPO date
Mar 24, 1986
Employees
Domiciled in
TR
Incorporated in
TR
Headquarters & legal address
Halkalı Merkez Mh. Basın Ekspres Cad. No.1 Küçükçekmece
İSTANBUL 34303
TR

Valuation

Title
TRY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT